This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE. Small-molecule PET tracers for imaging proteinopathies. Semin Nucl Med. 2017;47:553–75. https://doi.org/10.1053/j.semnuclmed.2017.06.003.
Goedert M, Yamaguchi Y, Mishra SK, Higuchi M, Sahara N. Tau filaments and the development of positron emission tomography tracers. Front Neurol. 2018;9:70 https://doi.org/10.3389/fneur.2018.00070.
Malarte ML, Gillberg PG, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01875-2.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9. https://doi.org/10.1038/sj.jcbfm.9600493.
Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19. https://doi.org/10.1001/jamaneurol.2020.2526.
Kroth H, Oden F, Molette J, Schieferstein H, Gabellieri E, Mueller A, et al. PI-2620 lead optimization highlights the importance of off-target assays to develop a PET tracer for the detection of pathological aggregated tau in Alzheimer’s disease and other tauopathies. J Med Chem. 2021;64:12808–30. https://doi.org/10.1021/acs.jmedchem.1c00861.
Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547:185–90. https://doi.org/10.1038/nature23002.
Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the Tau fibril: insight from computational modeling. ACS Chem Neurosci. 2018;9:1757–67. https://doi.org/10.1021/acschemneuro.8b00093.
Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimer’s Res Ther. 2017;9:96 https://doi.org/10.1186/s13195-017-0325-z.
Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J. 2006;36:652–60. https://doi.org/10.1111/j.1445-5994.2006.01153.x.
TJB has received funding from the Alzheimer’s Association and the National Institute on Aging under the grants listed below but has no other relevant disclosures. NIH/NIA R01AG021155, RF1AG027161, R01AG062285, P30AG062715, R01AG070883 and the Alzheimer’s Association AARF-19-614533.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Betthauser, T.J. In vitro evidence for a nonselective 4R tau PET tracer. Mol Psychiatry (2023). https://doi.org/10.1038/s41380-023-01950-2